Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOS172722 +/- Paclitaxel in Advanced Solid Tumors
NCT03328494Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bos172722 in solid tumor and triple-negative breast cancer (TNBC) (3 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Incidence of adverse events (AEs) at 3 months and Number of participants with a dose-limiting toxicity. Started Oct 2017; status: completed.
02
Drugs
bos172722
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03328494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328494.